Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Other Non-Current Liabilities came in at $278000.0 in Q1 2026, up 14.4% YoY from $243000.0 in Q1 2025, and down 99.73% on a QoQ basis from $102.8 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Other Non-Current Liabilities data on file, last reported at $278000.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 14.4% year-over-year to $278000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $278000.0 (up 14.4% YoY) and the FY2025 annual result came in at $260000.0, up 12.55% from the prior year.
- Other Non-Current Liabilities fell to $278000.0 in Q1 2026, from $102.8 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $165.0 million in Q2 2023 to a low of $227000.0 in Q2 2024.
- A 5-year average of $43.7 million and a median of $411000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities slumped 99.86% — and 2025, when it surged 52738.33%.
- Tracing ENTA's Other Non-Current Liabilities over 5 years: stood at $414000.0 in 2022, then surged by 56.76% to $649000.0 in 2023, then sank by 63.79% to $235000.0 in 2024, then surged by 43654.04% to $102.8 million in 2025, then slumped by 99.73% to $278000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $278000.0 (Q1 2026), $102.8 million (Q4 2025), and $260000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.29 Mn |
| Mar 31, 2026 | 278,000.00 |
| Dec 31, 2025 | 102.82 Mn |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 119.94 Mn |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 227,000.00 |
| Mar 31, 2024 | 147.78 Mn |
| Dec 31, 2023 | 649,000.00 |
| Sep 30, 2023 | 159.43 Mn |
| Jun 30, 2023 | 164.98 Mn |
| Mar 31, 2023 | 408,000.00 |
| Dec 31, 2022 | 414,000.00 |
| Jun 30, 2022 | 354,000.00 |
| Mar 31, 2022 | 876,000.00 |
| Dec 31, 2021 | 856,000.00 |
| Sep 30, 2021 | 558,000.00 |
| Jun 30, 2021 | 317,000.00 |